Qyuns Therapeutics Co., Ltd. (02509) disclosed a share repurchase conducted on 06 February 2026. The company repurchased 16,200 H shares on the Hong Kong Stock Exchange at a highest price of HKD 20.38 per share and a lowest price of HKD 20.06 per share, bringing the aggregate price paid to HKD 325,995.84.

Following this transaction, the company holds a total of 2,504,000 treasury shares, while the number of issued shares excluding treasury shares stands at 224,567,600. The overall total of issued shares is 227,071,600. According to the disclosure, the repurchase was made under a mandate authorized on 20 June 2025, which covers up to 22,207,160 shares. As of the announcement date, 2,504,000 shares (approximately 1.1276% of issued shares as of the mandate date) have been repurchased under this authorization. The moratorium period on new share issuances or transfers of treasury shares after the purchase extends to 08 March 2026.